JANUVIA
sitagliptin
- Strength
- 50 mg/1
- Form
- Tablet, Film Coated
- Class
- Dipeptidyl Peptidase 4 Inhibitor
Merck Sharp & Dohme LLC
Sitagliptin Hydrochloride Oral
Listed by Azurity Pharmaceuticals, Inc.
| Dosage form | Solution |
|---|---|
| Route | Oral |
| Drug class | Dipeptidyl Peptidase 4 Inhibitor |
| Approval route | NDA — original brand approval |
| NDC code | 24338-017 |
| FDA application | NDA219122 |
| RxNorm concept | 2716485 |
| Package sizes listed | 1 |
| Marketed since | April 2025 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
sitagliptin
Merck Sharp & Dohme LLC
sitagliptin
A-S Medication Solutions
sitagliptin
Cardinal Health 107, LLC
sitagliptin
A-S Medication Solutions
sitagliptin
Merck Sharp & Dohme LLC
sitagliptin
A-S Medication Solutions
sitagliptin
A-S Medication Solutions
sitagliptin
Cardinal Health 107, LLC
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.